Dihexa (PNB-0408)
PeptideDihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV-derived peptide that potentiates hepatocyte growth factor (HGF)/c-Met receptor signaling. Preclinical studies show remarkable cognitive enhancement at picomolar concentrations. In Alzheimer's disease mouse models, dihexa restored cognitive function and promoted synaptogenesis. Seven orders of magnitude more potent than BDNF in promoting dendritic spine formation. Currently investigational with no completed human clinical trials.
Quick Answer
What it is
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV-derived peptide that potentiates hepatocyte growth factor (HGF)/c-Met receptor signaling. Preclinical studies show remarkable cognitive enhancement at picomolar concentrations.
Key findings
- Grade C: Cognitive Enhancement (Cognitive Function)
- Grade C: Synaptogenesis (Cognitive Function)
- Grade C: Neuroprotection (Cognitive Function)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Dihexa (PNB-0408)
Quick Facts: Dihexa (PNB-0408)
- Best Evidence:Grade C
- Conditions Studied:1
- Research Outcomes:5
- Key Effect:Cognitive Function
Detailed Outcomes
Evidence by Condition
Research Citations (15)
Related Peptides
Tesamorelin
Peptide1 shared condition · 15 outcomes
Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved (2010) for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates endogenous pulsatile GH secretion from the pituitary gland. Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue, liver fat (NAFLD), and improving cognitive function in clinical trials.
Sermorelin
Peptide1 shared condition · 18 outcomes
Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency. Sermorelin stimulates natural GH release from the pituitary gland through the hypothalamic-pituitary axis, producing physiological GH patterns with built-in safety through somatostatin feedback regulation.
Semax
Peptide1 shared condition · 14 outcomes
Semax is a synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone). It has been approved as a prescription medication in Russia and Ukraine for treating stroke, cognitive disorders, and peptic ulcers. Research suggests it may enhance BDNF expression and exhibit nootropic and neuroprotective effects. Most clinical research has been conducted in Russia, with limited Western clinical trials.
Selank
Peptide1 shared condition · 9 outcomes
Selank is a synthetic heptapeptide derived from tuftsin, an immunomodulatory peptide. It has been approved in Russia as a treatment for anxiety and neurasthenic conditions. Research indicates it may have anxiolytic, nootropic, and immunomodulatory properties without sedative effects. Like Semax, most clinical research has been conducted in Russia.
Pinealon
Peptide1 shared condition · 4 outcomes
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Russian researchers as part of the Khavinson peptide bioregulators. It is designed to target brain tissue and has been studied for potential neuroprotective and cognitive-enhancing effects. Research suggests it may help regulate circadian rhythms and support cognitive function in aging, though human clinical data is limited.